Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3271-3276

  Diacon, A H ^a   Donald, P R ^a   Pym, A ^b   Grobusch, M ^c   Patientia, R F ^a   Mahanyele, R ^b   Bantubani, N ^c   Narasimooloo, R ^c   De Marez, T ^d   Van Heeswijk, R ^e   Lounis, N ^e   Meyvisch, P ^e   Andries, K ^e   McNeeley, D F ^d  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d Tibotec Inc   (United States)

^e TIBOTEC BVBA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; OFLOXACIN; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ACNE; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; HEARING IMPAIRMENT; HUMAN; LIMB PAIN; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; NAUSEA; PATIENT TRANSPORT; PHARMACOKINETICS; PILOT STUDY; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; RANDOMIZED CONTROLLED TRIAL; SPUTUM CULTURE; THORAX PAIN; TREATMENT DURATION; VIRUS INFECTION;

ANTITUBERCULAR AGENTS; CLARITHROMYCIN; CYCLOSERINE; DAPSONE; ERYTHROMYCIN; FEMALE; HUMANS; ISOXAZOLES; MALE; OFLOXACIN; OXAZOLIDINONES; QUINOLINES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84861140844     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06126-11     Document Type: Article

References (20)

1. Andries K, et al. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. (Pubitemid 40116230)
2. Calver AD, et al. 2010. Emergence of increased resistance and extensively drug-resistant tuberculosis despite treatment adherence, South Africa. Emerg. Infect. Dis. 16:264-271.
3. Canetti G, Rist N, Grosset J. 1963. Measurement of sensitivity of the tuberculous bacillus to antibacillary drugs by the method of proportions. Methodology, resistance criteria, results and interpretation. Rev. Tuberc. Pneumol. (Paris) 27:217-272. (In French.)
4. Chan ED, et al. 2004. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 169:1103-1109. (Pubitemid 38624789)
5. Diacon AH, et al. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med. 360:2397-2405.
6. Hanumegowda UM, et al. 2010. Phospholipidosis as a function of basicity, lipophilicity, and volume of distribution of compounds. Chem. Res. Toxicol. 23:749-755.
7. Heifets L. 2002. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J. Med. Microbiol. 51:11-12. (Pubitemid 34060127)
8. Johnson R, et al. 2006. Ethambutol resistance testing by mutation detection. Int. J. Tuberc. Lung Dis. 10:68-73. (Pubitemid 43266280)
9. Kent PT, Kubica GP. 1985. Public health mycobacteriology. U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control, Atlanta, GA.
10. Laszlo A, Rahman M, Espinal M, Raviglione M. 2002. Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/IUATLD Supranational Reference Laboratory Network: five rounds of proficiency testing, 1994-1998. Int. J. Tuberc. Lung Dis. 6:748-756. (Pubitemid 34988044)
11. Louw GE, et al. 2006. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. Int. J. Tuberc. Lung Dis. 10:802-807. (Pubitemid 44031396)
12. Mesens N, et al. 2010. Screening for phospholipidosis induced by central nervous drugs: comparing the predictivity of an in vitro assay to high throughput in silico assays. Toxicol. In Vitro 24:1417-1425.
13. Palomino JC, et al. 2002. Resazurin microtiter assay plate: simple and inexpensive method for detection of drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2720-2722.
14. Reasor MJ, Kacew S. 2001. Drug-induced phospholipidosis: are there functional consequences? Exp. Biol. Med. (Maywood) 226:825-830. (Pubitemid 34053231)
15. Rustomjee R, et al. 2008. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:2831-2835.
16. Satana D, Coban AY, Uzun M. 2010. Testing susceptibility of multidrug-resistant Mycobacterium tuberculosis to second-line drugs by use of blood agar. J. Clin. Microbiol. 48:4291-4293.
17. Seung KJ, et al. 2009. Early outcomes of MDR-TB treatment in a high HIV-prevalence setting in Southern Africa. PLoS One 4:e7186.
18. Warren RM, et al. 2006. Differentiation of Mycobacterium tuberculosis complex by PCR amplification of genomic regions of difference. Int. J. Tuberc. Lung Dis. 10:818-822. (Pubitemid 44031399)
19. World Health Organization. 2011. Global tuberculosis control 2011. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/ 2011/en/index.html.
20. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/2011/en/index.html.